| Literature DB >> 33268830 |
Ivetta Danylesko1,2, Roni Shouval3,4, Noga Shem-Tov3,4, Ronit Yerushalmi3,4, Elad Jacoby4,5, Michal J Besser4,6, Avichai Shimoni3,4, Tima Davidson4,7, Katia Beider3,4, Dror Mevorach8, Shalev Fried3,4, Arnon Nagler3,4, Abraham Avigdor3,4.
Abstract
We present three patients with aggressive non-Hodgkin's B-cell lymphoma (NHL) who received anti-CD19 chimeric antigen receptor T (CAR T) cells therapy after failure of several lines of chemotherapy that developed pseudo-progression. One-week clinical and radiological findings were consistent with tumor progression. Positron emission tomography-computed tomography (PET-CT) at 1 month post CAR T cells administration was consistent with treatment response. The rapid tumor growth and subsequent resolution are suggestive of tumor pseudo-progression mediated secondary to infiltration and immune activation of CAR T cells. Overall, 56 adult patients with NHL were enrolled in a phase 1b/2 in house clinical study with CD19 CAR T cells. Out of them 22/56 patients progressed as per PET-CT the 1 month post CAR T cells. In 14 patients, signs of progression started 7-10 days after CAR T cells infusion. In 11/14 patients, it was true progression, while in 3 it was pseudo-progression. Additional studies are warranted to describe the extent of this phenomenon and evaluate correlation with the CAR T activity and long-term disease control.Entities:
Mesh：
Substances：
Year: 2020 PMID： 33268830 PMCID： PMC8113054 DOI： 10.1038/s41409-020-01156-y
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483